Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
One-third of the U.S. population suffers from non-alcoholic fatty liver disease (NAFLD).
NAFLD is caused by diabetes and obesity, and is becoming more common. Although many people
have this disease, the change in how the liver handles drugs and compounds in the body has
not been studied. The purpose of this study is to investigate how advanced NAFLD changes the
ability of the liver to handle both endogenous and exogenous compounds.